The Illinois Biotechnology Industry Organization announced today that the election of new additions to its Board of Directors. The new Board Members, who involve senior executives and specialists from a very recognizable organizations, which add depth and validity to an already powerful lineup of medical, agricultural, and industrial biotech representation.
Joining the iBIO’s Board are David Flowers and Walt Johnston.
Walt Johnston is Vice President, US Marketing and Strategic New Product Planning
for Astellas Pharma US, inc., a global research pharmaceutical business who has dedicated their efforts to serving unmet medical needs in Oncology, Immunology, Cardiology, Infectious Diseases, Urology and Neuroscience.
“I am excited to join iBIO’s board during a period of unprecedented innovation and opportunity across the life sciences,” said Johnston. “I am looking forward to working with iBIO’s board members and staff to contribute to the future progress of the organization and the industry.”
“iBIO is fortunate to have members of Walt Johnston and David Flowers caliber join our board,” said Warren Ribley, iBIO President & CEO, “The leadership and experience that Walt and David bring to our board will be a great benefit to our organization and community.”
David Flowers is a Director, Life Sciences industry, for Deloitte Services LP. The subsidiaries of Deloitte LLP provide industry leading audit, consulting, tax and advisory services to a lot of the worlds most valued brands, involving 80 percent of the Fortune 500.
“Deloitte and iBIO have a strong collaborative history,” said Flowers. “Joining iBIO’s board provides me with the opportunity to continue to expand Deloitte’s contribution to the Illinois life sciences community.”